Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney

Tekijä Heerspink, Hiddo J L
Julkaisussa Nephrol Dial Transplant (2019)

Trial Design Innovations to Accelerate Therapeutic Advances in Chronic Kidney Disease: Moving from Single Trials to an Ongoing Platform

Tekijä Heerspink, Hiddo J.L., Perkovic, Vlado
Julkaisussa Clin J Am Soc Nephrol (2018)

Novel anti-inflammatory drugs for the treatment of diabetic kidney disease

Tekijä Heerspink, Hiddo J. L., De Zeeuw, Dick
Julkaisussa Diabetologia (2016)

Treating diabetic complications; from large randomized clinical trials to precision medicine

Tekijä Heerspink, Hiddo J. L., de Zeeuw, Dick
Julkaisussa Diabetes Obes Metab (2018)

Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy

Tekijä de Zeeuw, Dick, Heerspink, Hiddo J L
Julkaisussa Nephrol Dial Transplant (2020)

New clinical trial designs for establishing drug efficacy and safety in a precision medicine era

Tekijä Heerspink, Hiddo J. L., List, James, Perkovic, Vlado
Julkaisussa Diabetes Obes Metab (2018)

Editorial: The role of sodium-glucose cotransporter 2 inhibitors in the management of chronic kidney disease

Tekijä Heerspink, Hiddo J L, Fouque, Denis, Wanner, Christoph
Julkaisussa Nephrol Dial Transplant (2020)

Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease

Tekijä Pena, Michelle J., Mischak, Harald, Heerspink, Hiddo J. L.
Julkaisussa Diabetologia (2016)

ACCORDION: Ensuring That We Hear the Music Clearly

Tekijä Wong, Muh Geot, Heerspink, Hiddo J.L., Perkovic, Vlado
Julkaisussa Clin J Am Soc Nephrol (2018)

Exposure–response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials

Tekijä Koomen, Jeroen V., Stevens, Jasper, Heerspink, Hiddo J.L.
Julkaisussa Br J Clin Pharmacol (2020)

Precision medicine approaches for diabetic kidney disease: opportunities and challenges

Tekijä Tye, Sok Cin, Denig, Petra, Heerspink, Hiddo J L
Julkaisussa Nephrol Dial Transplant (2021)

New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors

Tekijä Dekkers, Claire C. J., Gansevoort, Ron T., Heerspink, Hiddo J. L.
Julkaisussa Curr Diab Rep (2018)

Multimarker Panels in Diabetic Kidney Disease: The Way to Improved Clinical Trial Design and Clinical Practice?

Tekijä Perco, Paul, Pena, Michelle, Heerspink, Hiddo J.L., Mayer, Gert
Julkaisussa Kidney Int Rep (2018)

Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus

Tekijä Vinke, Joanna Sophia J., Heerspink, Hiddo J.L., de Borst, Martin H.
Julkaisussa Curr Opin Nephrol Hypertens (2019)

No significant association of type 2 diabetes‐related genetic risk scores with glycated haemoglobin levels after initiating metformin or sulphonylurea derivatives

Tekijä Martono, Doti P., Heerspink, Hiddo J.L., Hak, Eelko, Denig, Petra, Wilffert, Bob
Julkaisussa Diabetes Obes Metab (2019)

Blood pressure‐lowering effects of sulodexide depend on albuminuria severity: post hoc analysis of the sulodexide microalbuminuria and macroalbuminuria studies

Tekijä Olde Engberink, Rik H. G., Heerspink, Hiddo J. L., de Zeeuw, Dick, Vogt, Liffert
Julkaisussa Br J Clin Pharmacol (2016)

Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects

Tekijä Heerspink, Hiddo J. L., Desai, Mehul, Jardine, Meg, Balis, Dainius, Meininger, Gary, Perkovic, Vlado
Julkaisussa J Am Soc Nephrol (2017)

Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?

Tekijä Weldegiorgis, Misghina, de Zeeuw, Dick, Dwyer, Jamie P., Mol, Peter, Heerspink, Hiddo J.L.
Julkaisussa Clin J Am Soc Nephrol (2017)

Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations

Tekijä Mol, Peter G. M., Thompson, Aliza, Heerspink, Hiddo J. L., Leufkens, Hubert G. M.
Julkaisussa Diabetes Obes Metab (2018)

Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin

Tekijä Kroonen, Marjolein Y. A. M., Stevens, Jasper, de Zeeuw, Dick, Heerspink, Hiddo J. L.
Julkaisussa Diabetes Obes Metab (2019)